Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease in Individuals With Type 1 Diabetes: A 12-Year Follow-up Study
2017/06/06 by Nordin M.J. Hanssen, Jean L.J.M. Scheijen, Anders Jorsal +6 · 28 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Advanced Glycation End Products research #Diabetes, Cardiovascular Risks, and Lipoproteins #Biochemical effects in animals
paper · doi:10.2337/db16-1578
Abstract
Methylglyoxal (MGO), a major precursor for advanced glycation end products, is increased in diabetes. In diabetic rodents, inhibition of MGO prevents cardiovascular disease (CVD). Whether plasma MGO levels are associated with incident CVD in people with type 1 diabetes is unknown. We included 159 individuals with persistent normoalbuminuria and 162 individuals with diabetic nephropathy (DN) from the outpatient clinic at Steno Diabetes Center. We measured MGO at baseline and recorded fatal and nonfatal CVD over a median follow-up of 12.3 years (interquartile range 7.6–12.5 years). Data were analyzed by Cox regression, with adjustment for sex, age, HbA1c, DN, diabetes duration, smoking, systolic blood pressure, antihypertensive medication, and BMI. During follow-up, 73 individuals suffered at least one CVD event (36 fatal and 53 nonfatal). Higher MGO levels were associated with total, fatal, and nonfatal incident CVD (hazard ratios [HRs] 1.47 [95% CI 1.13–1.91], 1.42 [1.01–1.99], and 1.46 [1.08–1.98], respectively). We observed a similar trend for total mortality (HR 1.24 [0.99–1.56]). This study shows for the first time in our knowledge that plasma MGO levels are associated with cardiovascular events in individuals with type 1 diabetes. MGO may explain, at least in part, the increased risk for CVD in type 1 diabetes.
Cited by
- Cardiovascular disease in type 1 diabetes, an underestimated danger: Epidemiological and pathophysiological data
- Placental Methylglyoxal in Preeclampsia: Vascular and Biomarker Implications
- Methylglyoxal and Its Adducts: Induction, Repair, and Association with Disease
- Skin autofluorescence predicts major adverse cardiovascular events in patients with type 1 diabetes: a 7-year follow-up study. [europepmc]
- Skin Autofluorescence-Indicated Advanced Glycation End Products as Predictors of Cardiovascular and All-Cause Mortality in High-Risk Subjects: A Systematic Review and Meta-analysis. [europepmc]
- Ameliorating Methylglyoxal-Induced Progenitor Cell Dysfunction for Tissue Repair in Diabetes. [europepmc]
- Urinary oxalate as a potential mediator of kidney disease in diabetes mellitus and obesity. [europepmc]
- Monocytes, Macrophages, and Metabolic Disease in Atherosclerosis. [europepmc]
- Dicarbonyl Stress at the Crossroads of Healthy and Unhealthy Aging. [europepmc]
- Attenuation of diabetic kidney injury in DPP4-deficient rats; role of GLP-1 on the suppression of AGE formation by inducing glyoxalase 1. [europepmc]
- Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease. [europepmc]
- Collagen methionine sulfoxide and glucuronidine/LW-1 are markers of coronary artery disease in long-term survivors with type 1 diabetes. The Dialong study. [europepmc]
- Association of the 1q25 Diabetes-Specific Coronary Heart Disease Locus With Alterations of the γ-Glutamyl Cycle and Increased Methylglyoxal Levels in Endothelial Cells. [europepmc]
- Advanced glycation endproducts and dicarbonyls in end-stage renal disease: associations with uraemia and courses following renal replacement therapy. [europepmc]
- Postprandial Glucose Spikes, an Important Contributor to Cardiovascular Disease in Diabetes? [europepmc]
- The metabolite methylglyoxal-mediated gene expression is associated with histone methylglyoxalation. [europepmc]
- Redox changes in obesity, metabolic syndrome, and diabetes. [europepmc]
- Advanced glycation end products as predictors of renal function in youth with type 1 diabetes. [europepmc]
- Methylglyoxal Scavengers Attenuate Angiogenesis Dysfunction Induced by Methylglyoxal and Oxygen-Glucose Deprivation. [europepmc]
- Dicarbonyl Stress in Diabetic Vascular Disease. [europepmc]
- Plasma Levels of Advanced Glycation Endproducts and Risk of Cardiovascular Events: Findings From 2 Prospective Cohorts. [europepmc]
- Honey: An Advanced Antimicrobial and Wound Healing Biomaterial for Tissue Engineering Applications. [europepmc]
- Methylglyoxal and Its Adducts: Induction, Repair, and Association with Disease. [europepmc]
- Pediatric Type 1 Diabetes: Mechanisms and Impact of Technologies on Comorbidities and Life Expectancy. [europepmc]
- Pathophysiology of Red Blood Cell Dysfunction in Diabetes and Its Complications. [europepmc]
- A Citrus and Pomegranate Complex Reduces Methylglyoxal in Healthy Elderly Subjects: Secondary Analysis of a Double-Blind Randomized Cross-Over Clinical Trial. [europepmc]
- Methylglyoxal in Cardiometabolic Disorders: Routes Leading to Pathology Counterbalanced by Treatment Strategies. [europepmc]
- Does Gut Microbial Methylglyoxal Metabolism Impact Human Physiology? [europepmc]
Related